Repligen Corporation Earnings Conference Call (Q2 2012) Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other Aug 2 Calls
Today's Calls
Call Details
Repligen Corporation Earnings Conference Call (Q2 2012)
Scheduled to start Thu, Aug 2, 2012, 8:30 am Eastern

-- this event is ongoing now--
Listen to the ongoing live event audio stream

About Repligen Corp (NasdaqGM:RGEN)Other Calls 
Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system. The company offers Protein A products, which are used in the production and purification of therapeutic monoclonal antibodies. Repligen also licenses its patent covering the use of CTLA4-Ig, a regulator of the activity of the immune system, and receives royalties from Bristol-Myers Squibb based on their U.S. Sales of Orencia. The company’s development stage products include RG1068, human secretin for improved MRI of the pancreas; RG2417, uridine for bipolar depression; HDAC inhibitors for Friedreich’s ataxia; and RG-SMA for spinal muscular atrophy. The company sells its Protein A products primarily through value-added resellers, as well as through distributors internationally. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials

Copyright © 2012 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2012 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.